louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05126420: MIYOPERİCYTOMA OF ORAL MUCOSE: CASE REPORT
Official title: A RARE TUMOR OF THE ORAL MUCOSE, MIYOPERİCYTOMA: CASE REPORT
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Myopericytoma
Keywords: oral pathology
mıyopericytoma
Lead sponsor: Ankara University
Sponsor class: OTHER
First posted: 2021-11-19
Enrollment: 1
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 1

Brief summary: Miyopericytoma (MPC) is defined as a benign tumor consisting mostly of oval-spindle-shaped myoid-appearing cells with perivascular growth. It may involve a single or multiple anatomical regions and may be multifocal and tends to occur mainly in the extremities, dermal and superficial soft tissues of adults. Cases of miyopericytoma due to trauma have been reported.Histological features and clinical course are generally benign, but features suggestive of low-grade malignancy were seen in MPCs. Myopericytoma in the oral and maxillofacial region is rare and a limited number of cases have been reported in the literature.

A 42-year-old female patient was admitted to our clinic with an enlarging lesion on the lingual aspect of the anterior mandible, which she noticed 2 years ago. As a result of the examination, a smooth-surfaced, off-white, pedunculated, fibrotic, painless, and non-bleeding lesion was detected in the lingual aspect of the anterior mandible. The lesion was removed by excisional biopsy.


Eligibility criteria: Inclusion Criteria:

Patient with a fibrotic lesion in the mouth

Exclusion Criteria:

Patient without fibrotic lesions in the mouth.

Primary outcomes:
measure: biopsy
timeFrame: 2 day
Secondary outcomes:
measure: recurrence
timeFrame: 1 year
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Elif Polat
Study officials:
affiliation: dtelifpolat@gmail.com
name: elif polat
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06544720: SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas
Official title: A Phase 1 Clinical Study of Autologous TCR-T Cells (SCG142) Therapy for Advanced HPV Associated Carcinomas
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Human Papillomavirus Associated Carcinomas
Cervical Cancer
Head and Neck Cancers
Anal Cancer
Vulva Cancer
Vaginal Cancer
Penile Cancer
HPV-Related Malignancy
Lead sponsor: The Affiliated Hospital of Qingdao University
Sponsor class: OTHER
First posted: 2024-08-09
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: A multicenter, open, single arm dose escalation and dose expansion phase I study to evaluate the safety, tolerability, and efficacy of SCG142 TCR-T cells in Subjects with advanced HPV associated carcinomas.


Eligibility criteria: Key Inclusion Criteria:

1. Greater than or equal to 18 years of age
2. HPV associated carcinomas
3. Patients must have at least one measurable lesion defined by RECIST 1.1
4. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

Key Exclusion Criteria:

1. Active or uncontrollable infections or other active major medical illnesses of the cardiovascular, respiratory.
2. Patients with active autoimmune diseases.
3. Patient has a known active Hepatitis B or Hepatitis C.
4. Other severe medical conditions that may limit subject\&#39;s participation in this trial.

Primary outcomes:
measure: DLT
timeFrame: 28 days
Secondary outcomes:
measure: Efficacy: antitumor activity of SCG142
timeFrame: 2 years
Other outcomes:
Locations:
city: Qingdao
country: China
facility: The affiliated hosptial of qingdao university
state: Shandong
Study officials:
References:
Clinical trial NCT00569920: Nausea and Pain Prophylaxis During Thyroid Surgery
Official title: Nausea and Pain Prophylaxis During Thyroid Surgery, a Comparison of Low-Dose and High-Dose Dexamethasone to Placebo
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Thyroid Diseases
Parathyroid Diseases
Lead sponsor: Sykehuset Telemark
Sponsor class: OTHER_GOV
First posted: 2007-12-10
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Postoperative pain and nausea may diminish a patient's wellbeing, and may also delay rehabilitation, as well as increase the total cost of care and treatment. Opioids are effective drugs for treatment of pain, but with the disadvantage of side effects such as somnolence and nausea. The benefits of various types of non-opioid analgesic in reducing patients' postoperative need for opioids have been well-documented.

One non-opioid prophylaxis documented for various surgery is short-term treatment with corticosteroids. The optimal dose of corticosteroids for peroperative nausea and pain prophylaxis is not well-documented. In our study we will attempt to determine whether the aforementioned benefits of corticosteroids are valid for a group of patients undergoing thyroid surgery.

Hypothesis: Single-dose treatment with dexamethasone provides a better analgesic effect and/or reduced use of opioids than placebo in patients undergoing elective throid surgery. Higher dose of dexamethasone provide better and/or longer-lasting analgesic effects without influencing the side effect profile.


Eligibility criteria: Inclusion Criteria:

* Inpatients scheduled for elective thyroid surgery and parathyroid surgery under general anesthesia.
* Informed consent

Exclusion Criteria:

* Patients who use steroids
* Patients who use antiemetics
* Patients who use opioid analgesics
* Body weight \> 100 kg
* BMI \> 35

Primary outcomes:
measure: Pain (VAS) and use of opioids. Nausea.
timeFrame: 30 days
Secondary outcomes:
measure: Nausea
timeFrame: 30 days
Other outcomes:
Locations:
city: Porsgrunn
country: Norway
facility: Surgery Unit, Porsgrunn, Acute Care Clinic, Telemark Hospital
state: Telemark
Study officials:
affiliation: Ullevål university hospital, Oslo university
name: Johan Raeder, Prof. M.D
role: STUDY_DIRECTOR
References:
Clinical trial NCT00967720: Barriers to Adherence to Asthma Controller Meds in Low Income Urban Minority Adolescents
Official title: Qualitative Analysis of the Barriers to Adherence With Asthma Controller Medication Among Inner City African American Adolescents as Identified Through Focus Group Data
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Asthma
Lead sponsor: Rush University Medical Center
Sponsor class: OTHER
First posted: 2009-08-28
Enrollment: 4
Sex: ALL
Minimum age (years): 12
Maximum age (years): 15
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: four low income urban adolescents with uncontrolled moderate persistent asthma

Brief summary: Poor adherence to appropriate asthma medications is an important risk factor contributing to high asthma morbidity and mortality in urban African American adolescents. As part of the ADEPT (Adolescent Disease Empowerment and Persistency Technology) for Asthma Pilot 2 study, a focus group was developed specifically to explore existing barriers to adherence among inner city African American adolescent asthmatics.


Eligibility criteria: Inclusion Criteria:

* 12-18 years of age
* self identify as African American
* have persistent asthma
* read at a minimum fourth grade reading level
* be on a prescribed daily inhaled corticosteroid medication for asthma

Exclusion Criteria:

* candidate refusal or presence of other co-morbidities

Primary outcomes:
measure: Focus groups explored whether a new communication medium improved adherence to asthma controller medications and to examine existing barriers to adherence among four urban African American adolescents with uncontrolled moderate persistent asthma
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Rush University Medical Center
name: Giselle S Mosnaim, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01040520: Value of CT-based Autopsy Compared With Conventional Autopsy in ICU Patients
Official title: Computertomography-based Autopsy (Virtopsy) Versus Conventional Autopsy in Patients Dying in Intensive Care Units
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Autopsy
Keywords: CT-based autopsy
virtual autopsy
medical autopsy
quality control
Lead sponsor: Universitätsklinikum Hamburg-Eppendorf
Sponsor class: OTHER
First posted: 2009-12-29
Enrollment: 284
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients who die while receiving treatment in the Department of Intensive Care Medicine

Brief summary: The aim of the study is to compare findings generated by CT-based autopsy (Virtopsy) with conventional autopsy and clinical diagnoses. Therefore all patients dying while receiving treatment in the Department of Intensive Care Medicine will be undergo virtopsy and, if relatives give informed consent conventional autopsy.

Detailed description: The aim of the study is to compare findings generated by computertomography-based autopsy (Virtopsy) with conventional autopsy and clinical diagnoses. Therefore all patients dying while receiving treatment in the Department of Intensive Care Medicine will be undergo virtopsy and, if relatives give informed consent conventional autopsy.

Eligibility criteria: Inclusion Criteria:

* Patients dying in the Department of Intensive Care Medicine while receiving treatment during the study period

Exclusion Criteria:

* None

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Wichmann D, Obbelode F, Vogel H, Hoepker WW, Nierhaus A, Braune S, Sauter G, Pueschel K, Kluge S. Virtual autopsy as an alternative to traditional medical autopsy in the intensive care unit: a prospective cohort study. Ann Intern Med. 2012 Jan 17;156(2):123-30. doi: 10.7326/0003-4819-156-2-201201170-00008.
Clinical trial NCT01782820: Influence of a Single Dose Dexamethasone on the Time Course of Neuromuscular Blockade of Rocuronium
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Neuromuscular Block, Dexamethasone
Neuromuscular Block, Recovery
Lead sponsor: Kreiskrankenhaus Dormagen
Sponsor class: OTHER
First posted: 2013-02-04
Enrollment: 108
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CROSSOVER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients of a primary care clinic undergoing elective gynecologic abdominal surgery

Brief summary: The aim of the present study is to compare the time course of a neuromuscular block in patients receiving dexamethasone 8 mg in order to reduce postoperative nausea or vomiting several hours before surgery with patients receiving the drug immediately before induction of anaesthesia and patients without a dexamethasone prophylaxis. The primary end point is the time from start of injection of rocuronium until recovery to a train of four ratio (TOF ratio) of 0.9.


Eligibility criteria: Inclusion Criteria:

* patients aged 18 to 65 years,
* American Society of Anesthesiologists Physical Status I or II,
* 50-90 kg body weight,
* undergoing elective laparoscopic gynaecological surgery in general anaesthesia necessitating intraoperative neuromuscular blockade.

Exclusion Criteria:

* expected difficulties with endotracheal intubation (history of difficult intubation,
* reduced opening of the mouth (\< 2cm), and Mallampati Score of 4),
* increased risk of pulmonary aspiration (gastrooesophageal reflux, full stomach, intestinal obstruction),
* known allergies to the drugs tested,
* pregnancy,
* neuromuscular disorders,
* intake of drugs affecting neuromuscular blockade, such as furosemide, magnesium or cephalosporins,
* hepatic-or renal insufficiency.

Primary outcomes:
measure: the time from start of injection of rocuronium until recovery to a train of four ratio (TOF ratio) of 0.9.
timeFrame: one hour
Secondary outcomes:
Other outcomes:
Locations:
city: Dormagen
country: Germany
facility: Kreiskrankenhaus Dormagen
Study officials:
References:
citation: Soltesz S, Fraisl P, Noe KG, Hinkelbein J, Mellinghoff H, Mencke T. Dexamethasone decreases the duration of rocuronium-induced neuromuscular block: a randomised controlled study. Eur J Anaesthesiol. 2014 Aug;31(8):417-22. doi: 10.1097/EJA.0b013e328365c9ee.
Clinical trial NCT04135820: A Phase I Study to Determine the Effect of Food on the Pharmacokinetic Profile of BPI-7711
Official title: An Open-label, Randomised, Single Dose, Cross-over Phase I Study to Determine the Effect of Food on the Pharmacokinetic Profile of BPI-7711
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: NSCLC
Lead sponsor: Beta Pharma, Inc.
Sponsor class: INDUSTRY
First posted: 2019-10-23
Enrollment: 16
Sex: MALE
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: OTHER

Brief summary: This is an open-label, randomised, single-dose, cross-over phase I study to evaluate the effect of food on the pharmacokinetic profile of BPI-7711 in Chinese healthy male subjects.


Eligibility criteria: Inclusion Criteria:

* Male, aged from 18 to 55 years.
* BMI from 18.5 to 28.0 kg/m2
* Medical history, vital signs, physical examination and lab tests are normal or abnormal without clinical significance.

Exclusion Criteria:

* Subjects with clinical significant diseases
* Subjects with allergic disease history
* Subjects with gastrointestinal disease history that can affect study drug absorption
* Subjects with drug abuse history

Primary outcomes:
measure: Cmax
timeFrame: Blood samples collected on Day 1 and Day 15 at pre-dose, 1, 2, 4, 5, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144 and 168 hours post BPI-7711 dose
measure: AUC(0-last)
timeFrame: Blood samples collected on Day 1 and Day 15 at pre-dose, 1, 2, 4, 5, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144 and 168 hours post BPI-7711 dose
Secondary outcomes:
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Shanghai Ninth People's Hospital
Study officials:
affiliation: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
name: Yongfang Yuan
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02161120: Effect of Two Different Rye Bread Types in Irritable Bowel Syndrome
Official title: Effects of Traditional and Low-FODMAP Rye Bread in Irritable Bowel Syndrome.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Irritable Bowel Syndrome
Keywords: IBS, irritable bowel syndrome, functional gastrointestinal disorder, diet, bread, rye, FODMAP, microbiota
Lead sponsor: Oy Karl Fazer Ab
Sponsor class: INDUSTRY
First posted: 2014-06-11
Enrollment: 87
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate if low-FODMAP (Fermented Oligo-, Di-, Monosaccharides And Polyols) rye bread is better tolerated in irritable bowel syndrome than commonly available traditional rye bread higher in FODMAP carbohydrates. The study also aims to investigate patients' compliance to rye bread regimen, potential changes is gut microbiota and hydrogen production during the test periods (a marker of large bowel fermentation of poorly absorbed carbohydrates).


Eligibility criteria: Inclusion Criteria:

* IBS according to Rome III criteria. Accepted sub-types include IBS-M, IBS-D and IBS-U
* Age 18-65 years
* Willing to use rye bread daily during the study periods

Exclusion Criteria:

* IBS-C (constipation dominant)
* Celiac disease
* IBD
* Major gastrointestinal operations like bowel gastric resection
* Non-treated hypo- or hyperthyroidism
* Alcoholism, severe depression, dementia, cancer or other diseases likely to severly impair the participants ability to conclude the protocol
* Regular (almost daily) use of NSAIDs, antibiotics or lactulose
* Linaclotide and other prescription medicines targeted specifically to IBS
* Pregnancy and lactation
* Follows currently strict low-FODMAP diet

Primary outcomes:
measure: Change is IBS symptoms by using IBS-SSS questionaire
timeFrame: 4 weeks
Secondary outcomes:
measure: IBS quality of life by using IBS QoL questionnaire
timeFrame: 4 weeks
measure: Changes in specific IBS symptoms measured by 100 mm VAS scale
timeFrame: 4 weeks
measure: Changes is intestinal microbiota evaluated by fecal samples
timeFrame: 4 weeks
measure: Changes in hydrogen excretion evaluated by 6 hours breath test after standard rye bread breakfast
timeFrame: 4 weeks
Other outcomes:
Locations:
city: Helsinki
country: Finland
facility: Aava Medical Centre
Study officials:
References:
citation: Laatikainen R, Jalanka J, Loponen J, Hongisto SM, Hillila M, Koskenpato J, Korpela R, Salonen A. Randomised clinical trial: effect of low-FODMAP rye bread versus regular rye bread on the intestinal microbiota of irritable bowel syndrome patients: association with individual symptom variation. BMC Nutr. 2019 Mar 6;5:12. doi: 10.1186/s40795-019-0278-7. eCollection 2019.
Clinical trial NCT05595720: Effect of High Intensity Laser on Hemiplegic Shoulder Dysfunction
Official title: Effect of High Intensity Laser on Hemiplegic Shoulder Dysfunction Double Blinded, Placebo-controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Stroke
Shoulder Dislocation or Subluxation
Keywords: Stroke,
Shoulder dysfunction
High intensity laser
Lead sponsor: Deraya University
Sponsor class: OTHER
First posted: 2022-10-27
Enrollment: 44
Sex: ALL
Minimum age (years): 40
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Hemiplegic shoulder pain (HSP) is a common and disabling complication following a stroke, and it may affect the quality of life. It often occurs following two to three months of stroke. Upper limb impairment is seen in 90% of patients affected by stroke.

Numerous causes have been implicated in developing HSP in stroke. This includes muscle flaccidity around the shoulder joint, shoulder subluxation, shoulder-hand syndrome, increased muscle tone, impingement syndrome, frozen shoulder, brachial plexus injury, and the thalamic syndrome.

Muscle paresis, abnormal muscle tone and loss of proprioception following stroke may render the shoulder complex unstable and therefore prone to misalignment.

In recent years, high-intensity laser therapy (HILT) has been considered as a treatment option for shoulder pain.

HILT increases microcirculation and tissue regeneration and lowers edema, inflammation, and pain with its photomechanical, thermal, electrical, and bio stimulating effects in deep tissues that cannot be reached with LILT.

It has some advantages over LILT, i.e., having higher power, greater tissue penetration capacity to deep tissues, the short emission time, and long rest periods preventing heat accumulation.

In recent studies, effectiveness of HILT has been shown in the treatment of subacromial impingement syndrome, rotator cuff tendinopathy, and frozen shoulder.


Eligibility criteria: Inclusion Criteria:

* DISORDER MORE THAN 6 MONTHS
* UNILATERAL
* FIRST TIME

Exclusion Criteria:

* Iinflammatory rheumatic disease,
* cervical radiculopathy,
* diabetes mellitus,
* thyroid disease,
* coronary heart disease,
* cardiac pacemaker,
* neurological disease,
* shoulder surgery, and
* shoulder injection in the last 3 months

Primary outcomes:
measure: PAIN score
timeFrame: 1 MONTH
measure: FUNCTION
timeFrame: 1 MONTH
Secondary outcomes:
Other outcomes:
Locations:
city: Minya
country: Egypt
facility: Physical Therapy
state: المنيا
Study officials:
References:
Clinical trial NCT06128720: Hyperbaric Oxygen Therapy for Optic Neuropathies
Official title: A Randomized, Sham Controlled, Masked Phase II Study to Evaluate the Neuroprotective Effect of Hyperbaric Oxygen Therapy on Optic Neuropathy
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Optic Neuropathy
Glaucoma
Lead sponsor: Stanford University
Sponsor class: OTHER
First posted: 2023-11-13
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to evaluate the neuroprotective efficacy of hyperbaric oxygen for the treatment in patients with optic neuropathy.


Eligibility criteria: Inclusion Criteria:

* Patients must meet all of the following criteria to join the study (all eligibility criteria must be met at the screening and baseline visits unless otherwise noted):
* Participant must be at least 18.
* Participant must has the ability to comply with the requirements of the study and complete the schedule of events (SOE).
* Participant's with clinical evidence of optic neuropathy.
* Participant must understand and sign the informed consent. If the participant's vision is impaired to the point where he/she cannot read the informed consent document, the document will be read to the participant in its entirety.

Exclusion Criteria:

* Participant is unable to comply with study procedures or follow-up visits.
* Participant has evidence of corneal opacification or lack of optical clarity.
* Participant is currently participating in or has within the last 3 months participated in any other clinical trial of a drug by ocular (if in the study eye) or systemic administration.
* Participant is pregnant or lactating.
* Participant has, in the opinion of the investigator, any physical or mental condition that would increase the risk of participation in the study or may interfere with the study procedures, evaluations and outcome assessments.
* Children and comatose patients.
* Participant abusing drugs or alcohol.
* Prior treatment with hyperbaric oxygen within the last 6 months.
* Participant with claustrophobia or that cannot decompress properly.

Primary outcomes:
measure: Change in Visual Field- Mean Deviation
timeFrame: Baseline through 6 months
measure: Change in Visual Field- Visual Field Index
timeFrame: Baseline through 6 months
Secondary outcomes:
measure: Change in Average Thickness Ganglion Cell Complex on Optical Coherence Tomography
timeFrame: Baseline through 6 months
measure: Change in Average Thickness Retinal Nerve Fiber Layer on Optical Coherence Tomography
timeFrame: Baseline through 6 months
Other outcomes:
Locations:
city: Palo Alto
country: United States
facility: Byers Eye Institute
state: California
Study officials:
affiliation: Stanford University
name: Jeffrey L Goldberg, MD PhD
role: STUDY_CHAIR
References: